• FirefoxInstall the new Firefox »
  •  Dow Down1.54% Nasdaq Down1.11%

    Keryx Biopharmaceuticals Inc. (KERX)

    12.56 Down 0.63(4.78%) 4:00PM EST
    |After Hours : 12.56 0.00 (0.00%) 4:40PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Keryx Biopharmaceuticals Inc.
    750 Lexington Avenue
    20th Floor
    New York, NY 10022
    United States - Map
    Phone: 212-531-5965
    Fax: 212-531-5961
    Website: http://www.keryx.com

    Index Membership:N/A
    Full Time Employees:155

    Business Summary 

    Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis. Zerenex has also completed a Phase II study for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with stages three to five non-dialysis dependent chronic kidney disease. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Keryx Biopharmaceuticals Inc.

    Corporate Governance 
    Keryx Biopharmaceuticals Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 5; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Ron Bentsur , 49
    Chief Exec. Officer, Director and Member of R&D Committee
    Mr. James F. Oliviero CFA, 39
    Chief Financial Officer and Treasurer
    Mr. Gregory P. Madison , 47
    Pres and Chief Operating Officer
    Dr. Enrique Poradosu Ph.D.,
    VP of Scientific & Bus. Strategy
    Ms. Lauren Fischer ,
    Director of Investor Relations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders